Glaucoma Insights

Pharmaceutical company files IND application with FDA for glaucoma candidate

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

Study highlights favorable two-year outcomes of standalone use of surgical system on mild to moderate open-angle glaucoma

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

Study: Gene therapy could preserve vision in patients with retinal disease, serious retinal injury

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

Studying glaucoma epidemiology at the center of the Earth

January 30, 2021

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.